Insider’s View: Deciphering BioXcel Therapeutics Inc (BTAI)’s Financial Health Through Ratios

Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The price of BioXcel Therapeutics Inc (NASDAQ: BTAI) closed at $0.56 in the last session, up 0.95% from day before closing price of $0.55. In other words, the price has increased by $0.95 from its previous closing price. On the day, 0.53 million shares were traded. BTAI stock price reached its highest trading level at $0.5644 during the session, while it also had its lowest trading level at $0.5373.

Ratios:

We take a closer look at BTAI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.25 and its Current Ratio is at 2.35.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on February 21, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $9 previously.

On August 15, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $40 to $4.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 03 ’24 when Wiley Matthew T. sold 6,272 shares for $0.55 per share. The transaction valued at 3,450 led to the insider holds 19,011 shares of the business.

Rodriguez Javier sold 6,863 shares of BTAI for $3,775 on Oct 03 ’24. The insider now owns 23,770 shares after completing the transaction at $0.55 per share. On Oct 03 ’24, another insider, Yocca Frank, who serves as the Chief Scientific Officer of the company, sold 7,175 shares for $0.55 each. As a result, the insider received 3,946 and left with 28,278 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BTAI now has a Market Capitalization of 22620956 and an Enterprise Value of 69972936. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.42. Its current Enterprise Value per Revenue stands at 29.119 whereas that against EBITDA is -0.671.

Stock Price History:

Over the past 52 weeks, BTAI has reached a high of $5.62, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is -17.62%, while the 200-Day Moving Average is calculated to be -71.43%.

Shares Statistics:

According to the various share statistics, BTAI traded on average about 568.16K shares per day over the past 3-months and 546940 shares per day over the past 10 days. A total of 40.74M shares are outstanding, with a floating share count of 32.45M. Insiders hold about 20.35% of the company’s shares, while institutions hold 24.15% stake in the company. Shares short for BTAI as of 1726185600 were 697630 with a Short Ratio of 1.23, compared to 1723680000 on 731185. Therefore, it implies a Short% of Shares Outstanding of 697630 and a Short% of Float of 2.1999999999999997.

Most Popular